Literature DB >> 8435103

Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents.

S Neben1, S Hellman, M Montgomery, J Ferrara, P Mauch, S Hemman.   

Abstract

High-dose chemotherapy and/or total body irradiation followed by autologous bone marrow rescue has improved the survival of patients with a variety of malignancies. Candidates for autologous bone marrow transplantation (ABMT) often have received prior exposure to cytotoxic agents, some of which may damage primitive stem cells. We have developed an in vivo murine model to evaluate the effects of a number of individual cytotoxic agents on the ability of syngeneic donor marrow to provide long-term hematopoiesis in recipients following high-dose total body irradiation. Marrow was experimentally obtained by giving donor mice 6 weekly injections of saline, cytosine arabinoside, cyclophosphamide, cisplatin, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), or busulfan, drugs known to have differing effects on primitive hematopoietic stem cells. After time to allow recovery of marrow and peripheral blood counts, 1 x 10(7) marrow cells from these mice were transplanted into lethally irradiated syngeneic recipients. Five to 6 months after marrow transplantation, the quality of long-term hematopoietic recovery was measured by WBC counts, marrow cellularity, CFU-S content, and determinations of stem cell self-renewal. Abnormalities were noted with the use of donor marrow exposed to all cytotoxic agents. Recipients of marrow previously exposed to cytosine arabinoside, an agent that spares the most primitive stem cells, were the least affected. Recipients of marrow previously exposed to busulfan, an agent known to damage primitive stem cells, were most affected with a decrease in peripheral blood counts, marrow cellularity, stem cell content, self-renewal capacity, and long-term survival. A decrease in hematopoietic stem cell self-renewal was seen in recipients of marrow previously exposed to cyclophosphamide, cisplatin, and BCNU even when marrow cellularity and CFU-S content were normal. These data suggest that the capacity of syngeneic donor marrow to provide long-term hematopoiesis in lethally irradiated recipients is dependent on its donor marrow primitive stem cell content. Long-term hematopoiesis may be severely compromised in recipients of donor stem cells previously exposed to cytotoxic agents which damage primitive stem cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8435103

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  14 in total

1.  Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers.

Authors:  Santosh Saraf; Hiroto Araki; Benjamin Petro; Youngmin Park; Simona Taioli; Kazumi G Yoshinaga; Emre Koca; Damiano Rondelli; Nadim Mahmud
Journal:  Transfusion       Date:  2014-11-02       Impact factor: 3.157

2.  Total body irradiation selectively induces murine hematopoietic stem cell senescence.

Authors:  Yong Wang; Bradley A Schulte; Amanda C LaRue; Makio Ogawa; Daohong Zhou
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

Review 3.  Hematopoietic stem cell injury induced by ionizing radiation.

Authors:  Lijian Shao; Yi Luo; Daohong Zhou
Journal:  Antioxid Redox Signal       Date:  2014-02-10       Impact factor: 8.401

4.  Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer.

Authors:  Zhannat Nurgalieva; Chih-Chin Liu; Xianglin L Du
Journal:  Med Oncol       Date:  2010-04-02       Impact factor: 3.064

5.  Hematopoietic stem cell senescence and cancer therapy-induced long-term bone marrow injury.

Authors:  Lijian Shao; Yingying Wang; Jianhui Chang; Yi Luo; Aimin Meng; Daohong Zhou
Journal:  Transl Cancer Res       Date:  2013-10       Impact factor: 1.241

Review 6.  Multiple myeloma, high-dose treatment and autologous stem cell transplantation--current status.

Authors:  B Björkstrand
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

7.  Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy.

Authors:  Yong Wang; Virginia Probin; Daohong Zhou
Journal:  Curr Cancer Ther Rev       Date:  2006-08-01

Review 8.  Myeloprotection by cytidine deaminase gene transfer in antileukemic therapy.

Authors:  Nico Lachmann; Sebastian Brennig; Ruhi Phaltane; Michael Flasshove; Dagmar Dilloo; Thomas Moritz
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

9.  Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent.

Authors:  R Maze; J P Carney; M R Kelley; B J Glassner; D A Williams; L Samson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

10.  Long-term polyclonal and multilineage engraftment of methylguanine methyltransferase P140K gene-modified dog hematopoietic cells in primary and secondary recipients.

Authors:  Brian C Beard; Reeteka Sud; Kirsten A Keyser; Christina Ironside; Tobias Neff; Sabine Gerull; Grant D Trobridge; Hans-Peter Kiem
Journal:  Blood       Date:  2009-03-31       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.